Fundamentals of deep brain stimulation for Parkinson's disease in clinical practice: part 1

Camila Henriques de Aquino; Mariana Moscovich; Murilo Martinez Marinho; Lorena Broseghini Barcelos; André C. Felício; Matthew Halverson; Clement Hamani; Henrique Ballalai Ferraz; Renato Puppi Munhoz

doi:10.1055/s-0044-1786026

Arquivos de Neuro-Psiquiatria, Inhaltsverzeichnis

CC BY 4.0 · Arq Neuropsiquiatr 2024; 82(04): s00441786026
DOI: 10.1055/s-0044-1786026

View and Review

Fundamentals of deep brain stimulation for Parkinson's disease in clinical practice: part 1

Princípios da estimulação cerebral profunda na doença de Parkinson na prática clínica: parte 1

Camila Henriques de Aquino

¹University of Calgary, Cumming School of Medicine, Department of Clinical Neurosciences, Calgary, AB, Canada.

²University of Calgary, Hotchkiss Brain Institute, Calgary, AB, Canada.

³Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brazil.

,

Mariana Moscovich

⁴Christian-Albrechts University, Department of Neurology, Kiel, Germany.

,

Murilo Martinez Marinho

³Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brazil.

,

Lorena Broseghini Barcelos

³Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brazil.

,

André C. Felício

⁵Hospital Israelita Albert Einstein, São Paulo SP, Brazil.

,

Matthew Halverson

⁶University of Utah, Department of Neurology, Salt Lake City, Utah, United States.

,

Clement Hamani

⁷University of Toronto, Sunnybrook Hospital, Toronto, ON, Canada.

,

Henrique Ballalai Ferraz

³Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brazil.

,

Renato Puppi Munhoz

⁸University of Toronto, Toronto Western Hospital, Toronto, ON, Canada.

› Institutsangaben

Abstract

Deep brain stimulation (DBS) is recognized as an established therapy for Parkinson's disease (PD) and other movement disorders in the light of the developments seen over the past three decades. Long-term efficacy is established for PD with documented improvement in the cardinal motor symptoms of PD and levodopa-induced complications, such as motor fluctuations and dyskinesias. Timing of patient selection is crucial to obtain optimal benefits from DBS therapy, before PD complications become irreversible. The objective of this first part review is to examine the fundamental concepts of DBS for PD in clinical practice, discussing the historical aspects, patient selection, potential effects of DBS on motor and non-motor symptoms, and the practical management of patients after surgery.

Resumo

Nas últimas três décadas, a estimulação cerebral profunda (ECP) se tornou um tratamento bem estabelecido para doença de Parkinson (DP) e outros transtornos do movimento. A eficácia a longo prazo na DP foi bem documentada para a melhora dos sintomas motores cardinais da DP e das complicações induzidas pelo uso do levodopa, como as flutuações motoras e as discinesias. O momento da seleção do paciente é crucial para se obter os benefícios ideais da ECP, antes que as complicações da DP se tornem irreversíveis. O objetivo desta primeira parte da revisão é examinar os conceitos fundamentais da ECP na prática clínica, discutindo os aspectos históricos, a seleção de pacientes, os potenciais efeitos da ECP nos sintomas motores e não motores da doença e o manejo prático dos pacientes após a cirurgia.

Keywords

Deep Brain Stimulation - Parkinson Disease - Neurosurgery

Palavras-chave

Estimulação Encefálica Profunda - Doença de Parkinson - Neurocirurgia

Bibliographical Record
Camila Henriques de Aquino, Mariana Moscovich, Murilo Martinez Marinho, Lorena Broseghini Barcelos, André C. Felício, Matthew Halverson, Clement Hamani, Henrique Ballalai Ferraz, Renato Puppi Munhoz. Fundamentals of deep brain stimulation for Parkinson's disease in clinical practice: part 1. Arq Neuropsiquiatr 2024; 82: s00441786026.
DOI: 10.1055/s-0044-1786026

Volltext

Referenzen

References
1 Cooper IS. Surgical alleviation of Parkinsonism; effects of occlusion of the anterior choroidal artery. J Am Geriatr Soc 1954; 2 (11) 691-718
2 Rand RW, Stern WE, Orr JK. Parkinsonism; early results of occlusion of the anterior choroidal artery. Calif Med 1954; 81 (04) 276-278
3 Guridi J, Lozano AM. A brief history of pallidotomy. Neurosurgery 1997; 41 (05) 1169-1180 , discussion 1180–1183
4 Gillingham J. Forty-five years of stereotactic surgery for Parkinson's disease: a review. Stereotact Funct Neurosurg 2000; 74 (3-4): 95-98
5 Okun MS, Vitek JL. Lesion therapy for Parkinson's disease and other movement disorders: update and controversies. Mov Disord 2004; 19 (04) 375-389
6 Speelman JD, Bosch DA. Resurgence of functional neurosurgery for Parkinson's disease: a historical perspective. Mov Disord 1998; 13 (03) 582-588
7 Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998; 339 (16) 1130-1143
8 Tasker RR, Siqueira J, Hawrylyshyn P, Organ LW. What happened to VIM thalamotomy for Parkinson's disease?. Appl Neurophysiol 1983; 46 (1-4): 68-83
9 Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76 (01) 53-61
10 Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249 (4975) 1436-1438
11 Aziz TZ, Peggs D, Agarwal E, Sambrook MA, Crossman AR. Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate. Br J Neurosurg 1992; 6 (06) 575-582
12 Hamada I, DeLong MR. Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding. J Neurophysiol 1992; 68 (05) 1859-1866
13 Nambu A. Seven problems on the basal ganglia. Curr Opin Neurobiol 2008; 18 (06) 595-604
14 Andy OJ, Jurko MF, Sias Jr FR. Subthalamotomy in Treatment of Parkinsonian Tremor. J Neurosurg 1963; 20: 860-870
15 Albe Fessard D, Arfel G, Guiot G. , et al; Characteristic Electric Activities of Some Cerebral Structures in Man. Ann Chir 1963; 17: 1185-1214
16 Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987; 50 (1-6): 344-346
17 Benabid AL, Pollak P, Seigneuret E, Hoffmann D, Gay E, Perret J. Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochir Suppl (Wien) 1993; 58: 39-44
18 Limousin P, Pollak P, Benazzouz A. et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995; 345 (8942) 91-95
19 Siegfried J, Lippitz B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery 1994; 35 (06) 1126-1129 , discussion 1129–1130
20 Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord 2015; 30 (01) 80-89
21 Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; 1 (8007) 345-349
22 Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23 (06) 837-844
23 Fox SH, Lang AE. Motor and non-motor fluctuations. Handb Clin Neurol 2007; 84: 157-184
24 Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311 (16) 1670-1683
25 Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20 (02) 224-230
26 Volkmann J. Deep brain stimulation for Parkinson's disease. Parkinsonism Relat Disord 2007; 13 (Suppl. 03) S462-S465
27 Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125 (Pt 4): 861-870
28 Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42 (06) 1142-1146
29 deSouza R-M, Moro E, Lang AE, Schapira AHV. Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?. Ann Neurol 2013; 73 (05) 565-575
30 Postuma RB, Berg D, Stern M. et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30 (12) 1591-1601
31 Bronstein JM, Tagliati M, Alterman RL. et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. In: Vol 68. 2011: 165
32 DeLong MR, Huang KT, Gallis J. et al. Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease. JAMA Neurol 2014; 71 (10) 1290-1295
33 Katz M, Kilbane C, Rosengard J, Alterman RL, Tagliati M. Referring patients for deep brain stimulation: an improving practice. Arch Neurol 2011; 68 (08) 1027-1032
34 Lang AE, Widner H. Deep brain stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord 2002; 17 (Suppl. 03) S94-S101
35 Lang AE, Houeto J-L, Krack P. et al. Deep brain stimulation: preoperative issues. Mov Disord 2006; 21 (Suppl. 14) S171-S196
36 Rughani AI, Hodaie M, Lozano AM. Acute complications of movement disorders surgery: effects of age and comorbidities. Mov Disord 2013; 28 (12) 1661-1667
37 Aquino CC, Lozano AM, Lang AE. Deep brain stimulation for Parkinson disease in elderly individuals. JAMA Neurol 2015; 72 (03) 367-367
38 Russmann H, Ghika J, Villemure J-G. et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 2004; 63 (10) 1952-1954
39 Derost P-P, Ouchchane L, Morand D. et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?. Neurology 2007; 68 (17) 1345-1355
40 Geraedts VJ, Feleus S, Marinus J, van Hilten JJ, Contarino MF. What predicts quality of life after subthalamic deep brain stimulation in Parkinson's disease? A systematic review. Eur J Neurol 2020; 27 (03) 419-428
41 Agid Y, Schüpbach M, Gargiulo M. et al. Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so?. J Neural Transm Suppl 2006; (70) 409-414
42 Schuepbach WMM, Rau J, Knudsen K. et al; EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368 (07) 610-622
43 Savica R, Matsumoto JY, Josephs KA. et al. Deep brain stimulation in benign tremulous parkinsonism. Arch Neurol 2011; 68 (08) 1033-1036
44 Welter ML, Houeto JL, Tezenas du Montcel S. et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 2002; 125 (Pt 3): 575-583
45 Defer GL, Widner H, Marié RM, Rémy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14 (04) 572-584
46 Saranza G, Lang AE. Levodopa challenge test: indications, protocol, and guide. J Neurol 2021; 268 (09) 3135-3143
47 Albanese A, Bonuccelli U, Brefel C. et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord 2001; 16 (02) 197-201
48 Fabbri M, Coelho M, Guedes LC. et al. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. Parkinsonism Relat Disord 2017; 39: 37-43
49 Warnecke T, Suttrup I, Schröder JB. et al. Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test. Parkinsonism Relat Disord 2016; 28: 100-106
50 Lechien JR, Blecic S, Ghosez Y, Huet K, Harmegnies B, Saussez S. Voice Quality and Orofacial Strength as Outcome of Levodopa Effectiveness in Patients with Early Idiopathic Parkinson Disease: A Preliminary Report. J Voice 2019; 33 (05) 716-720
51 Rodriguez RL, Fernandez HH, Haq I, Okun MS. Pearls in patient selection for deep brain stimulation. Neurologist 2007; 13 (05) 253-260
52 Brandão P, Grippe TC, Modesto LC. et al. Decisions about deep brain stimulation therapy in Parkinson's disease. Arq Neuropsiquiatr 2018; 76 (06) 411-420
53 Guy W. AIMS: ECDEU Assessment Manual for Psychopharmacology. Washington, DC:: Government Printing Office;; 1976
54 Goetz CG, Stebbins GT, Shale HM. et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994; 9 (04) 390-394
55 Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord 2008; 23 (16) 2398-2403
56 Chaudhuri KR, Martinez-Martin P, Brown RG. et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord 2007; 22 (13) 1901-1911
57 Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995; 4 (03) 241-248
58 Witt K, Daniels C, Reiff J. et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008; 7 (07) 605-614
59 Halpern CH, Rick JH, Danish SF, Grossman M, Baltuch GH. Cognition following bilateral deep brain stimulation surgery of the subthalamic nucleus for Parkinson's disease. Int J Geriatr Psychiatry 2009; 24 (05) 443-451
60 Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996; 53 (06) 538-542
61 Green J, McDonald WM, Vitek JL. et al. Cognitive impairments in advanced PD without dementia. Neurology 2002; 59 (09) 1320-1324
62 Marks Jr WJ. Deep Brain Stimulation Management. 2010
63 Dubois B, Burn D, Goetz C. et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007; 22 (16) 2314-2324
64 Llebaria G, Pagonabarraga J, Kulisevsky J. et al. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Disord 2008; 23 (11) 1546-1550
65 Skorvanek M, Goldman JG, Jahanshahi M. et al; members of the MDS Rating Scales Review Committee. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord 2018; 33 (02) 208-218
66 Castrioto A, Lhommée E, Moro E, Krack P. Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. Lancet Neurol 2014; 13 (03) 287-305
67 Moro E, Lang AE. Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Rev Neurother 2006; 6 (11) 1695-1705
68 Munhoz RP, Teive HA, Eleftherohorinou H, Coin LJ, Lees AJ, Silveira-Moriyama L. Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease. J Neurol Neurosurg Psychiatry 2013; 84 (08) 883-887
69 Kringelbach ML, Jenkinson N, Owen SLF, Aziz TZ. Translational principles of deep brain stimulation. Nat Rev Neurosci 2007; 8 (08) 623-635
70 Moro E, Lozano AM, Pollak P. et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 2010; 25 (05) 578-586
71 Weaver FM, Follett K, Stern M. et al; CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301 (01) 63-73
72 Kumar R, Lozano AM, Kim YJ. et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 1998; 51 (03) 850-855
73 Odekerken VJJ, van Laar T, Staal MJ. et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 2013; 12 (01) 37-44
74 Oyama G, Foote KD, Jacobson IV CE. et al. GPi and STN deep brain stimulation can suppress dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (07) 814-818
75 Bakker M, Esselink RAJ, Munneke M, Limousin-Dowsey P, Speelman HD, Bloem BR. Effects of stereotactic neurosurgery on postural instability and gait in Parkinson's disease. Mov Disord 2004; 19 (09) 1092-1099
76 Ricchi V, Zibetti M, Angrisano S. et al. Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: a 15 months follow-up study. Brain Stimul 2012; 5 (03) 388-392
77 Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR. Axial disability and deep brain stimulation in patients with Parkinson disease. Nat Rev Neurol 2015; 11 (02) 98-110
78 St George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010; 75 (14) 1292-1299
79 Burchiel KJ, Anderson VC, Favre J, Hammerstad JP. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery 1999; 45 (06) 1375-1382 , discussion 1382–1384
80 Wadon ME, Bailey GA, Yilmaz Z. et al. Non-motor phenotypic subgroups in adult-onset idiopathic, isolated, focal cervical dystonia. Brain Behav 2021; 11 (08) e2292
81 Hjort N, Østergaard K, Dupont E. Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord 2004; 19 (02) 196-199
82 Amara AW, Walker HC, Joop A. et al. Effects of subthalamic nucleus deep brain stimulation on objective sleep outcomes in Parkinson's disease. Mov Disord Clin Pract (Hoboken) 2017; 4 (02) 183-190
83 Becker N, Munhoz RP, Teive HAG. Lees' syndrome: a case series. Arq Neuropsiquiatr 2011; 69 (05) 756-759
84 Moum SJ, Price CC, Limotai N. et al. Effects of STN and GPi Deep Brain Stimulation on Impulse Control Disorders and Dopamine Dysregulation Syndrome. Oreja-Guevara C, ed. PLoS ONE. 2012; 7 (01) e29768
85 Sasikumar S, Matta R, Munhoz RP. et al. Advanced Therapies for the Management of Dopamine Dysregulation Syndrome in Parkinson's Disease. Mov Disord Clin Pract (Hoboken) 2021; 8 (03) 400-405
86 Voon V, Fernagut P-O, Wickens J. et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8 (12) 1140-1149
87 Broen M, Duits A, Visser-Vandewalle V, Temel Y, Winogrodzka A. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord 2011; 17 (06) 413-417
88 Fasano A, Romito LM, Daniele A. et al. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010; 133 (09) 2664-2676
89 Rouaud T, Dondaine T, Drapier S. et al. Pallidal stimulation in advanced Parkinson's patients with contraindications for subthalamic stimulation. Mov Disord 2010; 25 (12) 1839-1846
90 Videnovic A, Metman LV. Deep brain stimulation for Parkinson's disease: prevalence of adverse events and need for standardized reporting. Mov Disord 2008; 23 (03) 343-349
91 York MK, Dulay M, Macias A. et al. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2008; 79 (07) 789-795
92 Voon V, Krack P, Lang AE. et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008; 131 (Pt 10): 2720-2728